---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-089245"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:52:46.286877+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie settles RINVOQ patent litigation; no generic entry until at least April 2037

## Summary
- Settled litigation with all generic manufacturers over RINVOQ (upadacitinib) ANDAs.
- No generic entry expected before April 2037 in the US, assuming pediatric exclusivity.
- Extends AbbVie's market exclusivity for RINVOQ, a key immunology drug.
- Settlement and license agreements subject to standard acceleration provisions.
- Removes a significant overhang for AbbVie's revenue stream.

## SEC filing metadata
- accession: 0001104659-25-089245
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465925089245/0001104659-25-089245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465925089245/tm2525781d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-089245
- JSON: https://secwatch.observer/filing/0001104659-25-089245.json
- Plain text: https://secwatch.observer/filing/0001104659-25-089245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.